Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 25, 2025Advanced ScienceOpen Access

Drug Delivery Technologies for the Treatment of Age‐Related Macular Degeneration

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJ Jesus Rodriguez‐CruzJCJessica CutrufelloMLMichael Hon‐Wah Lam

Discussion

Loading...

Member takes

Overview

Review reveals challenges in AMD treatment using anti-VEGF injections, highlighting new drug delivery technologies.

Key Points

  • New drug delivery technologies aim to improve treatment outcomes for age-related macular degeneration, reducing patient discomfort.
  • Challenges include high costs and accessibility of current treatments, especially intravitreal injections of anti-VEGF.
  • The review critically evaluates recent research and innovative strategies to enhance drug delivery for AMD.
  • Future therapeutic approaches are explored, particularly the rising development of biosimilars in conjunction with current agents.

Cite This Study

Rodriguez‐Cruz et al. (2025) studied this question.

synapsesocial.com/papers/68af7df27567bf4f94ff4be2https://doi.org/10.1002/advs.202503212
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Advanced Drug Delivery Systems for Age‐Related Macular Degeneration Treatment: Latest Trends and Future Prospects2025
  2. 2Revolutionizing age-related macular degeneration treatment: Advances and future directions in non-invasive retinal drug delivery systems2025
  3. 3Recent advances in treating age-related macular degeneration and diabetic retinopathy: Current therapies and emerging novel approaches2025
  4. 4THE ROLE OF ANTI-VEGF THERAPY IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION: A COMPARATIVE ANALYSIS OF DRUG EFFICACY2025
  5. 5Gene Therapy for Wet Age-Related Macular Degeneration2025